Language

English

Publication Date

4-10-2026

Journal

Science Advances

DOI

10.1126/sciadv.aea8017

PMID

41961923

PMCID

PMC13068069

PubMedCentral® Posted Date

4-10-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and is largely driven by metabolic disorders such as obesity and type 2 diabetes. The AMP-activated protein kinase (AMPK) is a master regulator of metabolism, and its activation has been proposed as a therapeutic strategy for treating metabolic disorders. However, although AMPK activity is down-regulated in HCC, the precise role of AMPK in HCC development has not been clearly delineated. Here, we investigated the ability of constitutive AMPK activation to prevent HCC development using a constitutively active AMPK transgenic mouse model and a pharmacological AMPK activator. We observed that AMPK activation substantially reduced tumor formation in both diethylnitrosamine (DEN)-induced and streptozocin-induced (STAM) models of HCC via altered bile acid metabolism and inhibition of hepatic nuclear factor alpha (HNF4α) signaling. These findings provide mechanistic insights into AMPK biology and highlight the potential of AMPK as a therapeutic target, emphasizing the intricate interplay between metabolic dysregulation and cancer development.

Keywords

Animals, Hepatocyte Nuclear Factor 4, AMP-Activated Protein Kinases, Mice, Carcinoma, Hepatocellular, Enzyme Activation, Signal Transduction, Liver Neoplasms, Mice, Transgenic, Bile Acids and Salts, Diethylnitrosamine, Humans

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.